SOBI.ST - Swedish Orphan Biovitrum AB (publ)
| Previous close | 227.20 |
| Open | 226.80 |
| Bid | 221.60 x 0 |
| Ask | 221.80 x 0 |
| Day's range | 221.40 - 228.20 |
| 52-week range | 199.10 - 273.80 |
| Volume | |
| Avg. volume | 345,050 |
| Market cap | 66.655B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 21.29 |
| EPS (TTM) | 10.41 |
| Earnings date | 18 Jul 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 287.10 |
ZacksIs Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
Here is how Alcon (ALC) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
ZacksIs ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Here is how Adma Biologics (ADMA) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
Motley FoolWhy Shares of CTI BioPharma Are Soaring Wednesday
What happened Shares of CTI BioPharma (NASDAQ: CTIC) were up more than 80% early Wednesday after the company announced it was getting bought out for $1.7 billion by Swedish Orphan Biovitrum AB (OTC: BIOVF), also known as SOBI.
BloombergSweden’s Sobi to Buy CTI Biopharma for $1.7 Billion
(Bloomberg) -- Swedish Orphan Biovitrum AB agreed to buy US biotech CTI BioPharma Corp., which develops therapies for blood-related cancers, in a deal valued at $1.7 billion.Most Read from BloombergSteve Schwarzman Holds Off Giving Money to DeSantis After Meeting HimItaly Intends to Exit China Belt and Road Pact as Ties SourUS Inflation Shows Signs of Moderating, Giving Fed Room to PauseVanguard’s Trillion-Dollar Man Leads a Fixed-Income RevolutionTrump Liable for Sex Abuse, Must Pay $5 Million
- Reuters
Sweden's SOBI offers $1.7 billion to buy CTI BioPharma
Drugmaker Swedish Orphan Biovitrum (SOBI) said on Wednesday it had agreed to make a $1.7 billion cash offer for CTI BioPharma, a U.S. biopharmaceutical company focused on blood related cancers and rare diseases. SOBI said it would make a tender offer for $9.10 per CTI share, a premium of 89% over Tuesday's closing price of $4.82, to be partly funded via a share issue, sending CTI's stock sharply higher in early U.S. trade. The acquisition is aimed at expanding SOBI's rare haematology franchise, the company's CEO Guido Oelkers said in an interview.
ZacksSwedish Orphan Biovitrum (BIOVF) Q1 Earnings and Revenues Beat Estimates
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 54.55% and 5.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ZacksAstraZeneca (AZN), Sanofi Simply RSV Antibody Agreement Terms
AstraZeneca (AZN) and Sanofi (SNY) revise the contractual terms of the agreement for Beyfortus. Sanofi will have full commercial control of Beyfortus in the United States.
ZacksApellis' (APLS) Earnings Top, Empaveli Sales Boost Revenues
Apellis Pharmaceuticals (APLS) reports better-than-expected results, beating both earnings and revenue estimates. Empaveli sales continue to boost product revenues for the company.
ZacksSwedish Orphan Biovitrum (BIOVF) Beats Q3 Earnings Estimates
Swedish Orphan Biovitrum (BIOVF) delivered earnings and revenue surprises of 16.67% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ZacksAre Medical Stocks Lagging Alimera Sciences (ALIM) This Year?
Here is how Alimera Sciences (ALIM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
- Zacks
Is Swedish Orphan Biovitrum (BIOVF) Stock Outpacing Its Medical Peers This Year?
Here is how Swedish Orphan Biovitrum (BIOVF) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.
ZacksSwedish Orphan Biovitrum (BIOVF)'s Technical Outlook is Bright After Key Golden Cross
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ZacksIs Humana (HUM) Outperforming Other Medical Stocks This Year?
Here is how Humana (HUM) and Swedish Orphan Biovitrum (BIOVF) have performed compared to their sector so far this year.
ZacksHas Swedish Orphan Biovitrum (BIOVF) Outpaced Other Medical Stocks This Year?
Here is how Swedish Orphan Biovitrum (BIOVF) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.
Business WireADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
LAUSANNE, Switzerland, July 08, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan. The Marketing Authorization Application (MAA) for ZYNLONTA was validated by the European Medicines Agency (EMA) at the end of October 2021, and orphan d
ZacksSwedish Orphan Biovitrum (BIOVF) Stock Jumps 5.3%: Will It Continue to Soar?
Swedish Orphan Biovitrum (BIOVF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
